STOCK TITAN
  1. Home
  2. BCYPU

SAB BIOTHERAPEUTICS (BCYPU) Stock Price, News & Analysis

BCYPU NASDAQ

Company Description

This page collects what Stock Titan holds for BCYPU, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
0.00%
0.00
Last updated:
-
Performance 1 year
$0.0
Market Cap
11.9M
Shares outstanding

Latest News

View All
+0.24%

SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021

conferences
-1.17%

SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

clinical trial covid-19
0.00%

SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

management
+0.57%

SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19

clinical trial covid-19
+1.65%

SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19

covid-19
-0.10%

SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza

clinical trial

SAB BIOTHERAPEUTICS has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 2 with negative movement. Key topics include conferences, clinical trial, covid-19, management, acquisition. View all BCYPU news →

SEC Filings

View All

No SEC filings available for BCYPU.

Financial Highlights

—
Revenue (latest FY)
—
Net Income (latest FY)
—
Diluted EPS (latest FY)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months